Io Biotech Stock Investor Sentiment

IOBT Stock  USD 0.75  0.04  5.63%   
Slightly above 58% of all IO Biotech's private investors are looking to take a long position. The analysis of the overall investor sentiment regarding IO Biotech suggests that some traders are interested. IO Biotech's investing sentiment can be driven by a variety of factors including economic data, IO Biotech's earnings reports, geopolitical events, and overall market trends.
  

IO Biotech Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards IO Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at news.google.com         
IO Biotech Chief Medical Officer Awarded 518K Worth of Stock Options - IO Biotech - Benzinga
Google News at Macroaxis
over a year ago at www.macroaxis.com         
Acquisition by Ahmad Qasim Iftikhar of 288153 shares of IO Biotech subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
IO Biotech Strengthens Executive Management and US Presence ... - GlobeNewswire
Google News at Macroaxis
over a year ago at news.google.com         
OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in t...
Google News at Macroaxis
over a year ago at news.google.com         
10 Promising Biotech Stocks In The Medical Field - Securities.io
Google News at Macroaxis
over a year ago at news.google.com         
Cloud Startup Fly.io Raises 70 Million in EQT-Led Round - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Transforming Coherus Adds To IO Pipeline Via Merger With Surface ... - Generics Bulletin
Google News at Macroaxis
over a year ago at news.google.com         
FDA Pushes Review Time For GSKs Blood Cancer Therapy Added Via Sierra Oncology Acquisition - Yahoo F...
Google News at Macroaxis
over a year ago at simplywall.st         
We Think IO Biotech Needs To Drive Business Growth Carefully
Simply Wall St News at Macroaxis
over a year ago at marketwatch.com         
IO Biotech Shares Fall 26 percent on Dwindling Cash Reserves
marketwatch News
over a year ago at investing.com         
IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone
Investing News at Macroaxis
over a year ago at www.macroaxis.com         
Acquisition by Elling Christian E of 41533 shares of IO Biotech subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
Marketmind O Canada Markets wary of Fed hawkish surprise - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
ASCO Servier finds survival benefit in difficult brain cancer - FierceBiotech
Google News at Macroaxis
over a year ago at news.google.com         
IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program ...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about IO Biotech that are available to investors today. That information is available publicly through IOBT media outlets and privately through word of mouth or via IOBT internal channels. However, regardless of the origin, that massive amount of IOBT data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of IO Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of IO Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to IO Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive IO Biotech alpha.

IO Biotech Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
IO Biotech price target raised to 6 from 4 at Morgan Stanley - TipRanks
09/16/2024
2
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancers th Annual Meeting
10/04/2024
3
Acquisition by Vendola Keith A. of 69469 shares of IO Biotech at 14.0 subject to Rule 16b-3
10/11/2024
4
Insider Trading
10/21/2024
5
IO Biotech, Inc. Short Interest Down 12.7 percent in October
10/31/2024
6
IO Biotech Receives Buy Rating from HC Wainwright
11/07/2024
7
IO Biotech GAAP EPS of -0.36 misses by 0.09
11/12/2024
8
IO Biotech stock hits 52-week low at 0.73 amid market challenges By Investing.com - Investing.com South Africa
11/21/2024

Additional Tools for IOBT Stock Analysis

When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.